OK10 Stock Overview
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.36 |
| 52 Week High | US$2.84 |
| 52 Week Low | US$1.05 |
| Beta | -2.91 |
| 1 Month Change | 0% |
| 3 Month Change | -4.23% |
| 1 Year Change | -31.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OK10 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -1.4% |
| 1Y | -31.7% | -21.6% | 2.2% |
Return vs Industry: OK10 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: OK10 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| OK10 volatility | |
|---|---|
| OK10 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: OK10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OK10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 8 | Gary Jacob | www.okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.
OKYO Pharma Limited Fundamentals Summary
| OK10 fundamental statistics | |
|---|---|
| Market cap | €38.30m |
| Earnings (TTM) | -€15.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs OK10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OK10 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£6.85m |
| Gross Profit | -UK£6.85m |
| Other Expenses | UK£6.42m |
| Earnings | -UK£13.27m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -107.9% |
How did OK10 perform over the long term?
See historical performance and comparison